Director and PDMR Dealings
RNS & Investor News
Result of AGM
09 July 2021
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol, diabetes and skincare, announces that at the Annual General Meeting (ÒAGMÓ) held earlier today, all resolutions were duly passed.
As shareholders were unable to attend the AGM in person as a result of the ongoing pandemic, they were given the option to submit questions in advance. These questions have been addressed and will be available to view on the website, along with the voting results, later today: https://www.optibiotix-ir.com/content/investors/shareholder-information
For further information, please contact:
OptiBiotix Health plc
Neil Davidson, Chairman
Contact via Walbrook below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD)
Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker)
Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome Ð the collective genome of the microbes in the body Ð in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The CompanyÕs current areas of focus include obesity, cardiovascular health, and diabetes.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020